Pharmaceuticals

Revive Therapeutics (RVV.C) warned about overhype, but up 26% on clinical trial news

Oddball pharmaceutical player Revive Therapeutics (RVV.C) found itself on the back end of a warning by the BCSC this week, that certain German players in the smallcap promotion space had over-hyped the mushroom/cannabis/biotech deal and promised big wins inappropriately for anyone who invested. As a marketing partner of Revive, I got a few panicky texts from certain folks wondering if that meant trouble for us – or them. It’s not a problem for us; our coverage has been appropriately even-handed.

Read More »

Vinergy (VIN.C) thinks big

In 1856 a 34-year old French microbiologist named Louis Pasteur discovered that heating wine stopped it going bad.  Through scientific experimentation Pasteur determined the optimum

Read More »

Equity Guru Podcasts